|
|
Volumn 3, Issue 4, 2002, Pages 235-237
|
|
Zenarestat
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALDEHYDE REDUCTASE;
ALDOSE REDUCTASE INHIBITOR;
BETA 2 MICROGLOBULIN;
CREATININE;
EYE DROPS;
FR 901366;
GALACTOSE;
GLUCOSE;
GLUCURONIDE;
PLACEBO;
PONALRESTAT;
QUINAZOLINE DERIVATIVE;
SORBITOL;
STREPTOZOCIN;
URIC ACID;
ZENARESTAT;
ENZYME INHIBITOR;
AREA UNDER THE CURVE;
ASIA;
CATARACT;
CHINA;
CLINICAL TRIAL;
DIABETIC NEUROPATHY;
DIABETIC RETINOPATHY;
DOSE RESPONSE;
DRUG ACTIVITY;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG METABOLISM;
DRUG PROTEIN BINDING;
DRUG STRUCTURE;
EUROPE;
HUMAN;
JAPAN;
KIDNEY DISEASE;
LICENSING;
MOTOR NERVE CONDUCTION;
NEPHROTOXICITY;
NONHUMAN;
NOTE;
PERIPHERAL NEUROPATHY;
PHARMACODYNAMICS;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOUTH KOREA;
SURAL NERVE;
TAIWAN;
UNITED STATES;
XEROSTOMIA;
ANIMAL;
CHEMISTRY;
REVIEW;
STATISTICS;
ANIMALS;
CLINICAL TRIALS;
ENZYME INHIBITORS;
HUMANS;
QUINAZOLINES;
|
|
EID: 0037626919
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200203040-00003 Document Type: Note |
|
Times cited : (2)
|
|
References (10)
|
